Preliminary Report of Interferon α2b in Combination with Ribavirin for 48 Weeks for Treatment of Iranian Patients with Chronic Hepatitis C: a Quasi-Experimental Study

[摘要] Aim:Theadditionofribavirin(RIBA)tothestandardtreatmentwithinterferon(IFN)alphaledtoanimprovementinsustainedvirologicresponse(SVR)fromlessthan20%withIFNmonotherapyto40-45%incombinationtherapy.TheaimofthisstudyistoassessthetherapeuticefficacyandsafetyofIFNalpha(PDferon)incombinationwithRIBAonIranianpatientswithchronichepatitisC(CHC).Methods:48naivepatientsaged18yearsormorewithCHCwereenrolledandtreatedwith3megaunits(MU)IFNα-2bthreetimesaweekplus600-1000mgRIBAperdayfor48weeks.Follow-upaftertherapywas6months.Theefficacywasevidentattheendoftreatmentandattheendoffollow-upintermsofsustainednormalizationofalanineaminotransferaseandsustainedserumHCV-RNAloss.results:Therateofsustainedbiochemicalandvirologicresponsewere68.3%and78%,respectively.40patients(83.3%)hadatleastonenotseriouscomplicationand8patients(16.7%)didn’thaveanycomplication.Anypatientdidn’thaveseriouscomplication.conclusion:AlthoughwehadnocontrolgroupwhousedstandardIFN,ourpreliminaryfindingshowedacceptableandpromisingresponserateofPDferon.Ontheotherhand,itseemsthatadverseeventswithPDferonareaslikeasotherstandardIFNs.

[学科分类] 基础医学

[关键词] Interferon;Ribavirin;Hepatitis C;Treatment